GLP-1 drugs, such as Wegovy and Mounjaro, have shown promising results in helping people with obesity lose significant amounts of weight. These medications work by targeting hormonal pathways that regulate appetite and food intake. Wegovy contains semaglutide, which affects the GLP-1 hormone, while Mounjaro contains tirzepatide, which targets both GLP-1 and another hormone called GIP. Clinical trials have shown that people taking these drugs can lose up to 20% of their body weight over several months, often with the support of dietary and physical activity guidance. However, a recent analysis of prescription data in England has revealed a concerning trend. Private healthcare providers are prescribing these drugs at much lower rates in the most deprived areas, where obesity is more common. Even after accounting for the higher prevalence of obesity in these regions, the study found that people in the least deprived areas were prescribed these medications at a significantly higher rate. While the study does not directly link this gap to cost, it suggests that affordability and access may play a role in the disparity. Obesity is often viewed as a result of personal choices, but research shows that it is influenced by a complex mix of genetic, biological, and environmental factors. Lower socioeconomic status is strongly linked to a higher risk of obesity, particularly among women, due to factors like food prices, education, and living conditions. Healthier food choices tend to be more expensive, which can make it harder for people with limited resources to maintain a nutritious diet. Despite this, many obesity policies in England have focused on encouraging individual behavior change rather than addressing the underlying systemic issues that contribute to weight gain. The National Institute for Health and Care Excellence (NICE) recommends GLP-1 drugs for people with a BMI of at least 35 and a related health condition, with lower BMI thresholds for certain ethnic groups. While these medications are available through specialist NHS services, access through primary care is limited and being rolled out gradually. This means that many eligible patients may have to wait years for treatment. Private prescriptions offer an alternative for those who can afford them, but this may create a financial divide, as people in more deprived areas may struggle to access these drugs on time. Long-term use of GLP-1 drugs may be necessary to maintain weight loss, as studies show that people often regain a significant portion of lost weight after stopping treatment. These drugs can also reduce food intake, increasing the risk of nutrient deficiencies and muscle loss, which requires careful monitoring. Ensuring that patients receive proper nutritional and behavioral support is crucial, especially for those who already face food insecurity or have difficulty accessing healthcare. Without equitable access and support, the benefits of these drugs may not be fully realized, and health inequalities could widen.